News & Stories
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
New Evidence for Gene Replacement in a Mouse Model of Charcot-Marie-Tooth Disease
In an article published yesterday in Neurology Today, Dr. Kleopa demonstrated that gene replacement could be a viable treatment for recessive forms of CMT. CMT type 4C is a demyelinating disease, and this treatment both decreased the number of unmyelinated fibers and...
CMTRF Inks Milestone-Driven Partnership with AcuraStem to Repurpose Established Drugs for the Treatment of CMT
Focus will be on expansion of AcuraStem’s patient-based discovery platform, iNeuroRx™, to leverage patient neurons and advanced informatics technology to identify promising drugs ATLANTA (December 20, 2018) The newly launched CMT Research Foundation (CMTRF), a...
Fontan Surgery for Heart Defects May Not Be Advisable for CMT1A Patients, Case Study Finds
Charcot-Marie-Tooth News reports the findings of a study where patients with Charcot-Marie-Tooth disease (CMT) who undergo Fontan surgery to correct a heart defect in childhood may later develop difficulties with the diaphragm — the muscle that allows us to breath —...
Where We Started, How Far We Have Come and Where We are Going
The CMT Research Foundation offers hope to those living with CMT that a treatment and cure are on their way!
$1,000,000 pledge to CMT research
CMTRF Receives $1 Million Research Grant from Grandview Steers Foundation The pace of research for CMT just got faster. Atlanta (November 8, 2018) The newly launched CMT Research Foundation (CMTRF), the only 501(c)(3) not-for-profit organization focused solely on...
Key CMT Researchers added to Scientific Advisory Board
Gene Therapy, Adult Stem Cell and Clinical Experts are added to the CMT Research Foundation’s Scientific Advisory Board
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy